TrialA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Trial details
- Registry ID
- NCT07067463
- Phase
- Phase 3
Drug research
Orelabrutinib
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of Orelabrutinib in Patients With Primary Progressive Multiple SclerosisNCT07067463 | Zenas BioPharma (USA), LLC | Phase 3 | Recruiting | 2030-06Estimated |
| A Study of Orelabrutinib in Patients With Secondary Progressive Multiple SclerosisNCT07299019 | Zenas BioPharma (USA), LLC | Phase 3 | Recruiting | 2030-06Estimated |
A Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis
Trial details
- Registry ID
- NCT07299019
- Phase
- Phase 3
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |